James Quigley
Stock Analyst at Morgan Stanley
(1.04)
# 3,873
Out of 5,127 analysts
25
Total ratings
33.33%
Success rate
-2.4%
Average return
Main Sectors:
Stocks Rated by James Quigley
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KYMR Kymera Therapeutics | Maintains: Overweight | $73 → $127 | $79.11 | +60.54% | 7 | Dec 9, 2025 | |
| NVO Novo Nordisk | Maintains: Buy | $60 → $54 | $49.37 | +9.38% | 1 | Nov 28, 2025 | |
| NVS Novartis AG | Downgrades: Sell | $119 → $118 | $157.05 | -24.86% | 2 | Sep 12, 2025 | |
| SNY Sanofi | Initiates: Neutral | $65 | $48.27 | +34.66% | 1 | Mar 21, 2025 | |
| GRFS Grifols | Maintains: Neutral | $10 → $11 | $9.58 | +9.60% | 1 | Dec 5, 2023 | |
| GLPG Galapagos NV | Maintains: Equal-Weight | $42 → $40 | $33.60 | +19.05% | 10 | Aug 7, 2023 | |
| EVO Evotec SE | Upgrades: Overweight | $12 → $16 | $3.67 | +335.97% | 3 | Jun 23, 2023 |
Kymera Therapeutics
Dec 9, 2025
Maintains: Overweight
Price Target: $73 → $127
Current: $79.11
Upside: +60.54%
Novo Nordisk
Nov 28, 2025
Maintains: Buy
Price Target: $60 → $54
Current: $49.37
Upside: +9.38%
Novartis AG
Sep 12, 2025
Downgrades: Sell
Price Target: $119 → $118
Current: $157.05
Upside: -24.86%
Sanofi
Mar 21, 2025
Initiates: Neutral
Price Target: $65
Current: $48.27
Upside: +34.66%
Grifols
Dec 5, 2023
Maintains: Neutral
Price Target: $10 → $11
Current: $9.58
Upside: +9.60%
Galapagos NV
Aug 7, 2023
Maintains: Equal-Weight
Price Target: $42 → $40
Current: $33.60
Upside: +19.05%
Evotec SE
Jun 23, 2023
Upgrades: Overweight
Price Target: $12 → $16
Current: $3.67
Upside: +335.97%